All In Biotech

NDA 219947 · Arrowhead

Redemplo

Plozasiran Sodium · Subcutaneous · APOC-III-directed RNA Interaction; Small Interfering RNA

NovelBreakthrough therapyOrphan

CDER novel approval, Nov 18, 2025: To reduce triglycerides in adults with familial chylomicronemia syndrome

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Nov 18, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

7 Phase 3, 1 recruiting

FAERS reports

104

13 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 25, 2026.

REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is an apolipoprotein C-III ( apoC-III )-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). ( 1 )

Mechanism: Plozasiran is a siRNA conjugated with GalNAc that degrades the apoC-III mRNA through the RNA interference mechanism resulting in reduced levels of hepatic and serum apoC-III protein. Reduction of apoC- III protein leads to increased clearance of serum triglycerides.

Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 18, 2025 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • REDEMPLO · PLOZASIRAN SODIUM EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Plozasiran" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache21
  • nausea20
  • blood glucose increased15
  • injection site pain7
  • fatigue5
  • feeling abnormal5
  • hyperglycaemia5
  • blood triglycerides increased4
  • dizziness4
  • drug ineffective4
  • dyspnoea4
  • abdominal discomfort3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2026104

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: Arrowhead

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.